1816940-05-2
Chemical Structure
C5a Anaphylatoxin (human)
- CAS No.: 1816940-05-2
- Formula:C350H578N108O107S8
- Molecular Weight:8267.51
SMILES: O=C([C@@H](N)[C@@H](C)O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NC(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N1[C@H](C(N[C@H]2CCCNC(N)=N)=O)CCC1)=O)=O)CC(C)C)=O)CO)=O)[C@H](CC)C)=O)CCCNC(N)=N)=O)C)=O)C)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)CCC(O)=O)=O)CSSC[C@H](NC3=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(O)=O)CCCNC(N)=N)=O)=O)CC(C)C)=O)CCC(N)=O)=O)CCSC)=O)CC(O)=O)=O)CCCCN)=O)CC4=CNC=N4)=O)CO)=O)[C@H](CC)C)=O)CC(N)=O)=O)C)=O)CCCNC(N)=N)=O)CC(C)C)=O)CCC(N)=O)=O)CO)=O)C)=O)C(C)C)=O)C(C)C)=O)=O)[C@@H](C)O)=O)CCC(O)=O)=O)CC(O)=O)=O)CC(N)=O)=O)CC(N)=O)=O)C(C)C)=O)CS)=O)C)=O)=O)CC(O)=O)=O)CC5=CC=C(O)C=C5)=O)CSSC[C@@H]3NC6=O)=O)CSSC[C@H](NC2=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]6CCC(O)=O)=O)[C@@H](C)O)=O)CC7=CC=CC=C7)=O)C)=O)CCCCN)=O)[C@H](CC)C)=O)=O)CCCCN)=O)CCCCN)=O)C(C)C)=O)C(C)C)=O)CO)=O)CC8=CNC=N8)=O)CCCCN)=O)CC9=CC=C(O)C=C9)=O)CCCCN)=O)C)=O)C)=O)[C@H](CC)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)[C@H](CC)C)=O)CCCCN)=O)CCCCN)=O)CCC(N)=O)=O)CC(C)C
Biological Activity: C5a Anaphylatoxin (human) is a pro-inflammatory peptide and a leukocyte chemoattractant. C5a Anaphylatoxin (human) can be used to study inflammation and immunity, such as allergic asthma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
C5a Anaphylatoxin (human) | C5a Anaphylatoxin (human) is a pro-inflammatory peptide and a leukocyte chemoattractant. C5a Anaphylatoxin (human) can be used to study inflammation and immunity, such as allergic asthma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Monk PN, et al. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol. 2007 Oct;152(4):429-48. [Content Brief]
- [2]. Köhl J, et al. A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest. 2006 Mar;116(3):783-96. [Content Brief]
Keywords
